Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Antiviral PROTACs: Opportunity borne with challenge
Jinsen Liang, Yihe Wu, Ke Lan, et al.
Cell Insight (2023) Vol. 2, Iss. 3, pp. 100092-100092
Open Access | Times Cited: 32

Showing 1-25 of 32 citing articles:

Discovery of First-in-Class PROTAC Degraders of SARS-CoV-2 Main Protease
Yugendar R. Alugubelli, Jing Xiao, Kaustav Khatua, et al.
Journal of Medicinal Chemistry (2024) Vol. 67, Iss. 8, pp. 6495-6507
Open Access | Times Cited: 20
Target-based drug design strategies to overcome resistance to antiviral agents: opportunities and challenges
Shaoqing Du, Xueping Hu, Luis Menéndez‐Arias, et al.
Drug Resistance Updates (2024) Vol. 73, pp. 101053-101053
Closed Access | Times Cited: 14
Design, synthesis, and biological evaluation of first-in-class indomethacin-based PROTACs degrading SARS-CoV-2 main protease and with broad-spectrum antiviral activity
Jenny Desantis, Alessandro Bazzacco, Michela Eleuteri, et al.
European Journal of Medicinal Chemistry (2024) Vol. 268, pp. 116202-116202
Open Access | Times Cited: 11
Molecular glue degraders: exciting opportunities for novel drug discovery
Thomas Lemaître, Marie Cornu, Florian Schwalen, et al.
Expert Opinion on Drug Discovery (2024) Vol. 19, Iss. 4, pp. 433-449
Closed Access | Times Cited: 8
Discovery of Novel ERα and Aromatase Dual-Targeting PROTAC Degraders to Overcome Endocrine-Resistant Breast Cancer
Lilan Xin, Chao Wang, Yan Cheng, et al.
Journal of Medicinal Chemistry (2024) Vol. 67, Iss. 11, pp. 8913-8931
Closed Access | Times Cited: 8
Medicinal chemistry strategies towards the development of non-covalent SARS-CoV-2 Mpro inhibitors
Letian Song, Shenghua Gao, Bing Ye, et al.
Acta Pharmaceutica Sinica B (2023) Vol. 14, Iss. 1, pp. 87-109
Open Access | Times Cited: 20
Small Molecule Drugs Targeting Viral Polymerases
Deborah Palazzotti, Martina Sguilla, Giuseppe Manfroni, et al.
Pharmaceuticals (2024) Vol. 17, Iss. 5, pp. 661-661
Open Access | Times Cited: 7
Standing the test of COVID-19: charting the new frontiers of medicine
Simon Cauchemez, Giulio Cossu, Nathalie M. Delzenne, et al.
Frontiers in Science (2024) Vol. 2
Open Access | Times Cited: 6
“PROTAC” modified dihydroquinolizinones (DHQs) that cause degradation of PAPD-5 and inhibition of hepatitis A virus and hepatitis B virus, in vitro
You Li, Nicky Hwang, Andrew Snedeker, et al.
Bioorganic & Medicinal Chemistry Letters (2024) Vol. 102, pp. 129680-129680
Open Access | Times Cited: 5
Discovery of novel benzosultam CRBN ligands
Hoyeong Park, Santosh Shivanand Raikar, Yonghyo Kim, et al.
Bulletin of the Korean Chemical Society (2025)
Closed Access
A Comprehensive Primer and Review of PROTACs and Their In Silico Design
Jacopo Zattoni, Paola Vottero, Gea Carena, et al.
Computer Methods and Programs in Biomedicine (2025) Vol. 264, pp. 108687-108687
Open Access
Rational Proteolysis Targeting Chimera Design Driven by Molecular Modeling and Machine Learning
Shuoyan Tan, Zhuo Chen, Ruiqiang Lu, et al.
Wiley Interdisciplinary Reviews Computational Molecular Science (2025) Vol. 15, Iss. 2
Closed Access
Recent advances in PROTAC-based antiviral and antibacterial therapeutics
Can Zhou, Shiwei Yang, Jun Wang, et al.
Bioorganic Chemistry (2025), pp. 108437-108437
Closed Access
Integrating Proteolysis‐Targeting Chimeras (PROTACs) with Delivery Systems for More Efficient and Precise Targeted Protein Degradation
Jiachan Lin, Zirui Chen, Dan Zhang, et al.
Macromolecular Rapid Communications (2025)
Closed Access
Influenza A virus hemagglutinin: from classical fusion inhibitors to proteolysis targeting chimera-based strategies in antiviral drug discovery
Francisco Javier Hermoso-Pinilla, Aitor Valdivia, María‐José Camarasa, et al.
(2024), pp. 85-116
Open Access | Times Cited: 4
Novel Acyl Thiourea-Based Hydrophobic Tagging Degraders Exert Potent Anti-Influenza Activity through Two Distinct Endonuclease Polymerase Acidic-Targeted Degradation Pathways
Xiaoyu Ma, Xueyun Wang, Feifei Chen, et al.
Journal of Medicinal Chemistry (2024) Vol. 67, Iss. 11, pp. 8791-8816
Closed Access | Times Cited: 4
Recent advances in the molecular design and applications of proteolysis targeting chimera-based multi-specific antiviral modality
Yang Zhou, Shujing Xu, Nerea López-Carrobles, et al.
Acta Materia Medica (2023) Vol. 2, Iss. 3
Open Access | Times Cited: 10
Development of de-novo coronavirus 3-chymotrypsin-like protease (3CLpro) inhibitors since COVID-19 outbreak: A strategy to tackle challenges of persistent virus infection
Lei Tian, Taotao Qiang, Xiuding Yang, et al.
European Journal of Medicinal Chemistry (2023) Vol. 264, pp. 115979-115979
Closed Access | Times Cited: 9
Viral deubiquitinating proteases and the promising strategies of their inhibition
Vera Jannie Elisabeth van Vliet, Anuradha De Silva, Brian L. Mark, et al.
Virus Research (2024) Vol. 344, pp. 199368-199368
Open Access | Times Cited: 3
PROTAC unleashed: Unveiling the synthetic approaches and potential therapeutic applications
Narayanaperumal Pravin, Krzysztof Jóźwiak
European Journal of Medicinal Chemistry (2024) Vol. 279, pp. 116837-116837
Open Access | Times Cited: 3
Synergizing Proteolysis-Targeting Chimeras and Nanoscale Exosome-Based Delivery Mechanisms for HIV and Antiviral Therapeutics
Nobendu Mukerjee, Swastika Maitra, Arabinda Ghosh, et al.
ACS Applied Nano Materials (2024) Vol. 7, Iss. 4, pp. 3499-3514
Closed Access | Times Cited: 2
PROTAC Beyond Cancer- Exploring the New Therapeutic Potential o f Proteolysis Targeting Chimeras
Ritesh Bhole, S. Patil, Harshad S. Kapare, et al.
Current Topics in Medicinal Chemistry (2024) Vol. 24, Iss. 23, pp. 2050-2073
Closed Access | Times Cited: 2
Discovery of First-in-Class PROTAC Degraders of SARS-CoV-2 Main Protease
Yugendar R. Alugubelli, Jing Xiao, Kaustav Khatua, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2023)
Open Access | Times Cited: 5
Targeting the Ubiquitin Proteasome System to Combat Influenza A Virus: Hijacking the Cleanup Crew
Vandana Anang, Laura Antonescu, Richard Nho, et al.
Reviews in Medical Virology (2024) Vol. 34, Iss. 6
Open Access | Times Cited: 1
Nanoparticle-mediated delivery of peptide-based degraders enables targeted protein degradation
Souvik Ghosal, Cara M. Robertus, Jeanette Wang, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2024)
Open Access | Times Cited: 1
Page 1 - Next Page

Scroll to top